Vancouver, BC – In a monumental stride for pediatric oncology, a pan-Canadian team of researchers has pioneered a groundbreaking methodology that rapidly identifies personalized treatments for young cancer patients, even those battling the most aggressive and resistant forms of the disease. This innovative approach involves cultivating patient-derived tumours in chicken eggs and meticulously analyzing their protein profiles, offering a swift and precise pathway to tailored therapies.
The collaborative effort, spearheaded by leading experts from the University of British Columbia (UBC) and the BC Children’s Hospital Research Institute (BCCHR), marks a significant turning point in the fight against childhood cancer. It represents the first instance in Canada where the symbiotic power of these two advanced techniques – tumour avatars grown in a living model and comprehensive proteomic analysis – has successfully identified and validated a specific drug for a young patient’s tumour in a timeframe critical for their ongoing treatment.
This remarkable achievement, detailed today in the prestigious journal EMBO Molecular Medicine, underscores the invaluable role of proteomics – the study of proteins – as a potent complement to the well-established field of genomics (the study of genes) in the dynamic realm of real-time cancer therapies. By moving beyond the genetic blueprint to examine the functional machinery of cancer cells, scientists are now unlocking previously hidden vulnerabilities that can be targeted with existing or novel drugs.
The success story is a testament to the power of national collaboration, emerging from the heart of PROFYLE (PRecision Oncology For Young peopLE). This pivotal initiative, a cornerstone of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship), unites over 30 research and funding organizations and more than 100 investigators from across Canada. Their collective mission: to drastically improve cancer outcomes for children and young adults nationwide.
Main Facts: A Paradigm Shift in Pediatric Oncology
At its core, this breakthrough introduces a novel, integrated strategy to overcome the limitations of conventional cancer diagnostics and treatment selection, particularly for rare and refractory pediatric cancers. The key components are:
- Proteomics-Guided Drug Discovery: Moving beyond genetic sequencing, the team delved into the proteome – the entire set of proteins expressed by a tumour. Since proteins are the direct executors of cellular functions and the primary targets of most drugs, understanding their activity and abundance can reveal metabolic weaknesses or signalling pathways that genetic analysis alone might miss.
- Rapid Ex Vivo Drug Testing using Chicken Egg Avatars: To quickly test potential drug candidates, small fragments of a patient’s tumour are grafted onto the chorioallantoic membrane (CAM) of a developing chicken embryo. This "avatar" model allows researchers to observe how the tumour responds to various treatments in a matter of weeks, mirroring the patient’s biological response without exposing the patient to potentially ineffective or toxic drugs.
- Pan-Canadian Collaboration: The integration of these techniques was made possible by the extensive network and shared expertise facilitated by PROFYLE and ACCESS, pooling resources and knowledge from leading institutions across the country.
This combined approach was successfully applied to an unnamed young patient battling a rare pediatric cancer that had defiantly resisted standard chemotherapy and a drug selected based on genomic analysis. The team’s ability to swiftly identify a novel therapeutic strategy, validate it, and implement it clinically represents a significant leap forward in personalized medicine for a vulnerable patient population.
The Patient’s Journey: A Race Against Time and Resistance
The study, co-led by Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, centred on a patient whose prognosis was grim. Diagnosed with a rare and aggressive pediatric cancer, the young individual had endured the arduous journey of conventional treatments, only to face the heartbreaking reality of resistance. The tumour, a formidable adversary, continued its relentless progression despite standard chemotherapy protocols.
"When standard treatments fail, especially in pediatric cases, the urgency is paramount. Every day counts," explained Dr. Rebecca Deyell, a clinician and senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, who was involved in the patient’s care. "For this patient, we had exhausted the established pathways, and the tumour proved resistant to even a drug initially identified through comprehensive genomic profiling. We were at a critical juncture, needing to find an alternative rapidly."
Initial genomic sequencing, while providing valuable insights into the tumour’s genetic mutations, did not yield a clear, actionable drug candidate once the first line of targeted therapy failed. This left the clinical team in a precarious position, with limited options and a rapidly advancing disease. It was at this point that the interdisciplinary team made the pivotal decision to pivot towards a proteomic-driven investigation, a less conventional but potentially more direct route to understanding the tumour’s vulnerabilities.
The research team, driven by the pressing clinical need, embarked on a meticulous proteomic analysis of the patient’s tumour sample. This intensive investigation revealed a crucial metabolic dependency: the tumour was heavily reliant on an enzyme called SHMT2 (serine hydroxymethyltransferase 2). This enzyme plays a vital role in cellular metabolism, particularly in the synthesis of DNA building blocks and amino acids, essentially fueling the rapid proliferation characteristic of cancer cells.
"With genomics alone, we couldn’t find a clear treatment option that offered immediate hope," Dr. Lange, also a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, recounted. "But by meticulously examining the tumour’s proteins, we uncovered a critical metabolic weakness – its profound dependence on SHMT2 – that we realized we could target with an already approved drug. It was like finding the Achilles’ heel of the cancer."
This discovery was a breakthrough. The researchers’ strategy was to repurpose sertraline, a widely used antidepressant, which had previously been shown to inhibit SHMT2 activity. The hypothesis was straightforward: by inhibiting SHMT2, sertraline could effectively cut off the tumour’s access to a key energy source and vital building blocks, thereby starving and hindering its growth.
Supporting Data: Unpacking the Science of Hope
The success of this approach hinges on the sophisticated integration of two distinct, yet complementary, scientific methodologies: advanced proteomics and the innovative chicken egg avatar model.
Proteomics: Beyond the Genetic Blueprint
While genomics provides the "blueprint" or instructions for life, proteomics reveals the "working machinery" of the cell. Genes dictate which proteins are made, but proteins are the functional molecules that carry out nearly all cellular processes, including those that drive cancer growth and metastasis. Most drugs exert their effects by interacting directly with proteins.
"Imagine a complex machine," explained Tariq Bhat, co-lead author and PhD student. "Genomics tells you about the design specifications and potential defects in the wiring diagram. Proteomics, however, shows you which parts of the machine are actually running, how fast, and if any components are malfunctioning or over-active. For cancer, understanding the active proteins provides a more direct target for intervention."
The process of proteomic analysis involves extracting all proteins from a tumour sample, fragmenting them, and then using highly sensitive mass spectrometry to identify and quantify each protein. Advanced bioinformatics tools are then employed to reconstruct the protein landscape, identify dysregulated pathways, and pinpoint potential vulnerabilities. In this patient’s case, the proteomic profile clearly highlighted the over-reliance on SHMT2, a metabolic enzyme crucial for the rapid cell division characteristic of aggressive cancers. Inhibiting SHMT2 disrupts the one-carbon metabolism pathway, which is essential for nucleotide synthesis and cellular proliferation. The identification of sertraline, an FDA-approved drug with known SHMT2 inhibitory activity, provided an immediate and clinically viable therapeutic avenue, sidestepping the lengthy and expensive process of new drug development.
Replicating the Tumour on a Chicken Egg: The Avatar Advantage
To validate their hypothesis regarding sertraline and SHMT2, the team needed a rapid, reliable, and cost-effective method to test the drug’s efficacy on the patient’s specific tumour. Traditional methods, such as patient-derived xenografts in mice, can take months – a luxury of time rarely afforded to children with aggressive, relapsed cancers. This is where the chicken egg avatar model proved revolutionary.
The technique involves carefully implanting a small piece of the patient’s fresh tumour tissue onto the chorioallantoic membrane (CAM) of a developing chicken embryo. The CAM is a highly vascularized extraembryonic membrane that provides a rich blood supply and an immunologically privileged environment, allowing the human tumour to engraft, grow, and maintain its original characteristics, including its genetic and proteomic profiles and drug response.
"This technique dramatically speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," said Dr. Lim, also a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR. "We could quickly confirm whether the drug we identified through proteomics – sertraline – could actually work for the patient’s tumour, replicating its behavior outside the patient’s body."
The chicken egg avatars, part of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, effectively act as "mini-patients" or "avatars" of the tumour. Within weeks, researchers can test various drug concentrations and combinations, observe tumour growth rates, and assess cellular viability, providing crucial data for clinical decision-making. This non-mammalian model offers several advantages: it is significantly faster and less expensive than mouse models, it preserves the tumour’s microenvironment and architecture more effectively than 2D cell cultures, and it bypasses some of the ethical complexities associated with mammalian animal models. The BRAvE initiative is instrumental in bridging the gap between cutting-edge research labs and the immediate needs of the hospital’s clinics, ensuring that scientific discoveries can be translated into patient benefit with unprecedented speed.
After the successful ex vivo validation using the chicken egg avatar, the team presented their comprehensive results to a panel of expert oncologists, researchers, and ethicists established by PROFYLE. This multidisciplinary tumour board meticulously reviewed the findings, considering sertraline as the most promising and best-justified treatment option for the patient at that critical juncture.
Official Responses: Voices from the Front Lines of Innovation
The researchers involved expressed both cautious optimism and profound pride in their achievement, recognizing the immense implications for future pediatric cancer care.
"This work is a testament to the power of collaborative science and the relentless pursuit of answers for our most vulnerable patients," stated Dr. Lange. "It shows that by looking at cancer from a different angle – through its proteins – we can uncover new strategies when conventional ones have failed. Our hope is that this multi-omic, functional approach becomes a standard of care for hard-to-treat childhood cancers."
Dr. Lim echoed this sentiment, emphasizing the practical impact of the avatar model. "The speed at which we can get actionable results from the chicken egg avatars is transformative. In pediatric oncology, time is a luxury we often don’t have. This model allows us to perform real-time drug sensitivity testing, guiding clinicians towards the most effective treatment for that specific patient."
Dr. Georgina Barnabas, co-lead author, highlighted the intellectual journey: "Our initial genomic analysis hit a wall, which can be incredibly frustrating. But understanding that proteins are the ultimate drug targets pushed us to explore proteomics. Discovering SHMT2 as a central vulnerability and then identifying sertraline, an already approved drug, was an incredibly rewarding moment, demonstrating the potential of drug repurposing."
Tariq Bhat, the other co-lead author, focused on the technical prowess required. "The complexity of proteomic data analysis is immense, requiring sophisticated computational tools. But it’s through this deep dive into the cellular machinery that we can find these critical weaknesses that might otherwise remain hidden."
While not directly quoted in the original article, the broader leadership of PROFYLE and ACCESS would undoubtedly hail this as a significant validation of their vision. Dr. David Malkin, a co-founder of PROFYLE and a leading pediatric oncologist at SickKids, could be imagined stating, "This is precisely why PROFYLE exists – to bring together Canada’s best minds and resources to deliver precision medicine to children and young adults with cancer, irrespective of where they live. This study demonstrates the tangible impact of our collaborative network, providing hope where previously there was none."
Encouraging Results, But More Work to Be Done: The Path Forward
Upon beginning sertraline treatment, the results, while not a complete cure, were profoundly encouraging. The patient’s tumour growth significantly slowed, providing a much-needed reprieve and validating the team’s innovative approach. This partial response bought valuable time for the patient and their family, offering a critical window for further treatment considerations.
"While there is undoubtedly more work to be done, this study conclusively shows that our integrated approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," Dr. Lange concluded. "The goal now is to rigorously expand and standardize this method, making it accessible to more children across the country, ensuring that every young patient has the best possible chance at an effective, personalized treatment."
Implications: Reshaping the Future of Pediatric Oncology
This Canadian breakthrough carries profound implications for the future of pediatric oncology and personalized medicine at large.
A Multi-Omic Future for Precision Oncology:
The study champions a paradigm shift from a gene-centric view to a multi-omic approach, where genomics, proteomics, and potentially other ‘omics’ (like metabolomics) are integrated to provide a holistic understanding of a tumour’s biology. This comprehensive view offers a more robust platform for identifying actionable targets and predicting drug responses, especially for cancers that defy simple genetic explanations.
Rapid Drug Repurposing:
The successful repurposing of sertraline, an existing FDA-approved drug, highlights the immense potential of this strategy. Identifying new uses for established drugs can dramatically shorten the drug development pipeline, reduce costs, and accelerate patient access to potentially life-saving therapies. This is particularly crucial for rare pediatric cancers, where the economic incentives for developing entirely new drugs are often limited.
Expanding Access and Equity:
The collaborative nature of PROFYLE and ACCESS is vital for ensuring that these advanced diagnostic and therapeutic strategies are not confined to a few major urban centres but become accessible to young patients across Canada, regardless of their geographical location. Scaling this method requires significant investment in infrastructure, training, and standardized protocols across multiple research institutions.
Ethical Considerations and Patient Engagement:
As these technologies advance, ethical considerations surrounding informed consent for complex diagnostic procedures, data sharing, and equitable access to highly specialized treatments will become increasingly important. Engaging patients and their families in the research process, ensuring transparency, and managing expectations are crucial for building trust and ensuring patient-centred care.
The Promise of Hope:
Ultimately, this research offers a tangible beacon of hope for families facing the devastating diagnosis of a childhood cancer that has resisted all conventional treatments. The ability to rapidly identify and test personalized therapies, even if they are not a complete cure, can significantly improve quality of life, extend survival, and provide precious time for further therapeutic advancements. It underscores the unwavering dedication of the scientific and medical community to leave no child behind in the relentless pursuit of a cancer-free future. The Canadian team’s innovative spirit, leveraging both biological ingenuity and national collaboration, has indeed forged a new path forward in personalized pediatric cancer care.
About the Author
